Quizartinib (AC220): a promising option for acute myeloid leukemia
Fang Zhou, Zheng Ge, Baoan ChenDepartment of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of ChinaAbstract: Quizartinib is an effective therapy for patients with FLT3-ITD a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-04-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/quizartinib-ac220-a-promising-option-for-acute-myeloid-leukemia-peer-reviewed-article-DDDT |
| _version_ | 1818535170687369216 |
|---|---|
| author | Zhou F Ge Z Chen B |
| author_facet | Zhou F Ge Z Chen B |
| author_sort | Zhou F |
| collection | DOAJ |
| description | Fang Zhou, Zheng Ge, Baoan ChenDepartment of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of ChinaAbstract: Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells. Multiple clinical trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation. In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib. We also summarize clinical experiences and adverse effects with quizartinib and recommend crucial approaches of quizartinib in the therapy of patients with newly diagnosed AML and patients with relapsed/refractory AML, particularly those with FLT3-ITD mutation. Quizartinib presents its advantages as a very promising agent in the treatment of AML, especially in patients with FLT3-ITD mutations. FLT3/ITD mutation can lead to constitutive autophosphorylation of FLT3 and activation of its downstream effectors including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT5 signal pathways, while Quizartinib can inhibit these downstream pathways through specific FLT3 inhibition. Quizartinib has received US Food and Drug Administration breakthrough therapy designation in patients with relapsed/refractory FLT3-ITD AML based on clinical trials. A larger sample of clinical trials are needed to verify its safety and efficacy, and the efficacy of quizartinib combined with chemotherapy or allogeneic hematopoietic cell transplantation should also be estimated in clinical trials. Meanwhile, for the side effects of quizartinib, further studies are needed to find a way to reduce its toxicity.Keywords: quizartinib, FLT3 inhibitor, FLT3-ITD mutation, AML, clinical trials, targeted therapy |
| first_indexed | 2024-12-11T18:21:14Z |
| format | Article |
| id | doaj.art-086b621df0e848c8a399913e33832324 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-11T18:21:14Z |
| publishDate | 2019-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-086b621df0e848c8a399913e338323242022-12-22T00:55:14ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-04-01Volume 131117112544985Quizartinib (AC220): a promising option for acute myeloid leukemiaZhou FGe ZChen BFang Zhou, Zheng Ge, Baoan ChenDepartment of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of ChinaAbstract: Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells. Multiple clinical trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation. In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib. We also summarize clinical experiences and adverse effects with quizartinib and recommend crucial approaches of quizartinib in the therapy of patients with newly diagnosed AML and patients with relapsed/refractory AML, particularly those with FLT3-ITD mutation. Quizartinib presents its advantages as a very promising agent in the treatment of AML, especially in patients with FLT3-ITD mutations. FLT3/ITD mutation can lead to constitutive autophosphorylation of FLT3 and activation of its downstream effectors including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT5 signal pathways, while Quizartinib can inhibit these downstream pathways through specific FLT3 inhibition. Quizartinib has received US Food and Drug Administration breakthrough therapy designation in patients with relapsed/refractory FLT3-ITD AML based on clinical trials. A larger sample of clinical trials are needed to verify its safety and efficacy, and the efficacy of quizartinib combined with chemotherapy or allogeneic hematopoietic cell transplantation should also be estimated in clinical trials. Meanwhile, for the side effects of quizartinib, further studies are needed to find a way to reduce its toxicity.Keywords: quizartinib, FLT3 inhibitor, FLT3-ITD mutation, AML, clinical trials, targeted therapyhttps://www.dovepress.com/quizartinib-ac220-a-promising-option-for-acute-myeloid-leukemia-peer-reviewed-article-DDDTQuizartinibFLT3 inhibitorFLT3-ITD mutationAMLClinical tricalsTargeted therapy |
| spellingShingle | Zhou F Ge Z Chen B Quizartinib (AC220): a promising option for acute myeloid leukemia Drug Design, Development and Therapy Quizartinib FLT3 inhibitor FLT3-ITD mutation AML Clinical tricals Targeted therapy |
| title | Quizartinib (AC220): a promising option for acute myeloid leukemia |
| title_full | Quizartinib (AC220): a promising option for acute myeloid leukemia |
| title_fullStr | Quizartinib (AC220): a promising option for acute myeloid leukemia |
| title_full_unstemmed | Quizartinib (AC220): a promising option for acute myeloid leukemia |
| title_short | Quizartinib (AC220): a promising option for acute myeloid leukemia |
| title_sort | quizartinib ac220 a promising option for acute myeloid leukemia |
| topic | Quizartinib FLT3 inhibitor FLT3-ITD mutation AML Clinical tricals Targeted therapy |
| url | https://www.dovepress.com/quizartinib-ac220-a-promising-option-for-acute-myeloid-leukemia-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT zhouf quizartinibac220apromisingoptionforacutemyeloidleukemia AT gez quizartinibac220apromisingoptionforacutemyeloidleukemia AT chenb quizartinibac220apromisingoptionforacutemyeloidleukemia |